oclacitinib and Cat-Diseases

Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats.. Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values.. Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats.

Topics: Animals; Cat Diseases; Cats; Female; Male; Pyrimidines; Random Allocation; Sulfonamides

The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects.. Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12h for 2 weeks and then at 1 mg/kg q24h for a further 2 weeks. At the study outset (D0), and 7 (D7) and 28 (D28) days after starting treatment, clinical lesions were assessed using a validated scoring system (SCORing Feline Allergic Dermatitis [SCORFAD]) and pruritus was graded via an adapted visual analogue scale (PVAS). At the same time points, plasma oclacitinib levels and haematological variables were measured.. Oclacitinib emerged as being safe and effective to control clinical signs of FASS. A mean dose of 1 mg/kg, even without extending twice-daily treatment beyond the first 2 weeks, could be a suitable therapeutic regimen. Plasma drug levels did not seem useful to predict clinical response during treatment.

Topics: Animals; Cat Diseases; Cats; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Pyrimidines; Sulfonamides

Toxoplasma gondii is a ubiquitous protozoan, for which felids are the definitive host. Immunocompromised individuals are susceptible to recrudescent toxoplasmosis. This case describes a 6-year-old, feline immunodeficiency virus-positive domestic short hair cat with feline atopic skin syndrome that developed fatal toxoplasmosis after treatment with oclacitinib for five months.. Toxoplasma gondii est un protozoaire ubiquitaire dont les félidés sont l'hôte définitif. Les personnes immunodéprimées sont sensibles à la toxoplasmose recrudescente. Ce cas décrit un chat domestique à poils courts de 6 ans, positif pour le virus de l'immunodéficience féline, atteint du syndrome atopique cutané félin, qui a développé une toxoplasmose mortelle après un traitement à l'oclacitinib pendant cinq mois.. Toxoplasma gondii es un protozoo ubicuo, cuyo huésped definitivo son los felinos. Las personas inmunocomprometidas son susceptibles a la toxoplasmosis recrudescente. Este caso describe un gato doméstico de pelo corto positivo para el virus de la inmunodeficiencia felina de 6 años de edad con síndrome de piel atópica felina, que desarrolló toxoplasmosis fatal después del tratamiento con oclacitinib durante cinco meses.. Toxoplasma gondii ist ein ubiquitäres Protozoon, für welches Felidae den definitiven Wirt darstellen. Immunkompromitierte Individuen sind empfänglich für eine sich verschlimmernde Toxoplasmose. Dieser Fall beschreibt eine 6 Jahre alte Hauskatze, die auf das Feline Immunodefizienz Virus positiv getestet war und am felinen atopischen Hautsyndrom litt, welche nach einer 5 monatigen Behandlung mit Oclacitinib eine fatale Toxoplasmose entwickelte.. Toxoplasma gondiiは，ネコ科動物を宿主とする至る所にある原虫である。免疫不全を起こしていると再発性トキソプラズマ症に罹患しやすい。本症例は、猫アトピー性皮膚症候群の猫免疫不全ウイルス陽性ドメスティック・ショート・ヘアー(6歳)が、オクラシチニブによる5カ月間の治療後に致死的なトキソプラズマ症を発症したものである。.. 弓形虫是一种普遍存在的原虫，猫科动物是其终末宿主。免疫功能低下者易患复发性弓形虫病。该病例描述了1只患有猫特应性皮肤综合征的6岁家养短毛猫，猫免疫缺陷病毒阳性，在接受奥拉替尼治疗5个月后发生致死性弓形虫病。.. Toxoplasma gondii é um protozoário ubíquo para o qual os felídeos são o hospedeiro definitivo. Indivíduos imunocomprometidos são suscetíveis a toxoplasmose recrudescente. Este relato descreve um caso de um felino doméstico de pelo curto de seis anos de idade, positivo para o vírus da imunodeficiência felina, com síndrome atópica felina, que desenvolveu toxoplasmose fatal após tratamento com oclacitinib por cinco meses.

Topics: Animals; Cat Diseases; Cats; Dermatitis, Atopic; Immunodeficiency Virus, Feline; Pyrimidines; Sulfonamides; Toxoplasma; Toxoplasmosis, Animal

Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Glucocorticoids; Pruritus; Pyrimidines; Sulfonamides

Pemphigus foliaceous (PF) is a pustular, immune-mediated skin disease characterised by acantholytic cells and commonly treated with high doses of glucocorticoids. This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases.. Le pemphigus foliacé (PF) est une dermatose à médiation immune pustuleuse caractérisée par des cellules acantholytiques et traitée fréquemment par des doses élevées de corticoïdes. Cet article décrit un cas de PF félin contrôlé avec succès par de l’oclacitinib orale, suggérant une alternative thérapeutique possible aux corticoïdes dans certains cas.. El pénfigo foliáceo (PF) es una enfermedad cutánea pustular, inmunomediada, caracterizada por células acantolíticas y comúnmente tratada con altas dosis de glucocorticoides. Este informe describe un caso de PF El pénfigo foliáceo (PF) es una enfermedad cutánea pustulosa, inmunomediada, caracterizada por células acantolíticas y comúnmente tratada con altas dosis de glucocorticoides. Este informe describe un caso de FP felino controlado con éxito con oclacitinib oral, lo que sugiere una posible alternativa terapéutica a los glucocorticoides en algunos casos. felino controlado con éxito con oclacitinib oral, lo que sugiere una posible alternativa terapéutica a los glucocorticoides en algunos casos.. Pemphigus foliaceus (PF) ist eine pustulöse, immun-mediierte Hauterkrankung, die durch akantholytische Zellen charakterisiert wird und häufig mit hohen Dosen an Glukokortikoiden behandelt wird. Dieser Fallbericht beschreibt den Fall eines felinen PF, der erfolgreich mit Oclacitinib per os kontrolliert wurde, was einen Hinweis darauf liefert, dass es sich dabei in manchen Fällen um eine therapeutische Alternative zu Glukokortikoiden handeln könnte.. 葉状天疱瘡（PF）は、免疫介在性膿疱性皮膚疾患で、棘融解細胞が特徴であり、一般的に高用量のグルココルチコイド製剤で治療される。本報告では、猫PFの1例がオクラシチニブマレイン酸塩の経口投与でコントロールに成功したことを報告しており、症例によってはオクラシチニブマレイン酸塩はグルココルチコイドに代わる治療法である可能性を示唆している。.. 落叶型天疱疮(PF)是一种脓疱性、免疫介导的皮肤病，以棘层松解细胞为特征，常用高剂量糖皮质激素治疗。本报告描述了1个口服奥拉替尼成功控制猫PF的病例，表明某些病例的治疗可能以此替代糖皮质激素。.. O pênfigo foliáceo (PF) é uma dermatopatia pustular, imunomediada caracterizada por células acantolíticas e comumente tratado com altas doses de glicocorticoides. Este relato descreve um caso de PF felino satisfatoriamente controlado utilizando oclacitinib por via oral, sugerindo uma possível alternativa terapêutica aos glicocorticoides em alguns casos.

Topics: Animals; Cat Diseases; Cats; Glucocorticoids; Pemphigus; Pyrimidines; Sulfonamides

Oclacitinib is a Janus kinase inhibitor that decreases pruritus and lesions in allergic dogs. In cats, it is able to inhibit interleukin-31-induced pruritus; no information is available on its clinical effectiveness.. To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis.. Cats >12 months of age and >3 kg body weight with a diagnosis of nonflea-, nonfood-induced hypersensitivity dermatitis were treated with oclacitinib, 0.4-0.6 mg/kg orally (p.o.) twice daily for 2 weeks, then once daily for an additional 14 days. Clinical lesions were evaluated with the Scoring Feline Allergic Dermatitis (SCORFAD) system and pruritus was evaluated with a 10-cm-long visual analog scale (VAS) before and at the end of the study. Owners assessed global efficacy, ease of administration and tolerability with a four-point scale.. Twelve cats were treated with a mean initial oclacitinib dose of 0.47 mg/kg p.o. twice daily. There was good improvement in SCORFAD and VAS pruritus scores in five of 12 cases, while the other cats were unchanged, deteriorated or dropped out due to treatment failure. Owners scored global efficacy as good/excellent in four of 12 cases and ease of administration and tolerability as good/excellent in 10 of 12.. Oclacitinib at 0.4-0.6 mg/kg p.o. may be an effective and safe drug for some cats with nonflea-, nonfood-induced hypersensitivity dermatitis. Further studies are needed to identify the most effective dose range for this species.

Topics: Animals; Cat Diseases; Cats; Dermatitis, Atopic; Dermatologic Agents; Female; Male; Pilot Projects; Prospective Studies; Pyrimidines; Sulfonamides; Treatment Outcome